Cargando…

Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan

PURPOSE: This prospective post-marketing surveillance (PMS) was designed to collect data on the safety and effectiveness of naldemedine in routine clinical practice in patients with opioid-induced constipation (OIC) and cancer pain in Japan and explore the characteristics of patients prone to diarrh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takata, Keiko, Nakazawa, Masami, Honda, Keiichi, Hashimoto, Sayo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942924/ https://www.ncbi.nlm.nih.gov/pubmed/35044484 http://dx.doi.org/10.1007/s00520-022-06807-y

Ejemplares similares

Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan
por: Naya, Noriyuki, et al.
Publicado: (2023)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022)

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
por: Kamiya, Teruhiko, et al.
Publicado: (2023)

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
por: Ozaki, Anna, et al.
Publicado: (2022)

A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
por: Webster, Lynn R, et al.
Publicado: (2020)

Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
por: Stern, Emily K, et al.
Publicado: (2018)

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study
por: Nishiba, Hiromi, et al.
Publicado: (2022)

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019)

Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2022)

Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
por: Wild, James, et al.
Publicado: (2020)

Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation
por: Kanemasa, Toshiyuki, et al.
Publicado: (2019)

Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives
por: Hale, Martin E., et al.
Publicado: (2021)

Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies
por: Camilleri, Michael, et al.
Publicado: (2021)

Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018)

A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
por: Webster, Lynn R, et al.
Publicado: (2017)

Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials
por: Wild, James, et al.
Publicado: (2019)

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study
por: Webster, Lynn R., et al.
Publicado: (2018)

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol
por: Higashibata, Takahiro, et al.
Publicado: (2022)

Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study
por: Hiruta, Eriko, et al.
Publicado: (2021)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine
por: Fukumura, Kazuya, et al.
Publicado: (2019)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Naldemedine: A New Option for OIBD
por: Coluzzi, Flaminia, et al.
Publicado: (2020)

Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis
por: Ishii, Koji, et al.
Publicado: (2019)

Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): A Post Hoc Analysis
por: Tokoro, Akihiro, et al.
Publicado: (2021)

Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation
por: Chokhavatia, Sita, et al.
Publicado: (2016)

Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study
por: Takagi, Yusuke, et al.
Publicado: (2020)

Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
por: Kubota, Ryuji, et al.
Publicado: (2018)

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018)

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
por: Kakimoto, Yoshihide, et al.
Publicado: (2021)

Abdominal Pain due to Opioid-Induced Constipation
por: Jacobs, Chelsea, et al.
Publicado: (2019)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

A Survey of the Incidence of Constipation in Patients with Chronic Non-cancer Pain Using Opioid Analgesics in Japan
por: Sonohata, Motoki, et al.
Publicado: (2022)

Fentanyl/naldemedine: Diarrhoea and decreased peristalsis: case report
Publicado: (2021)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study
por: Okamoto, Akiharu, et al.
Publicado: (2021)

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation
por: Sloots, Cornelius E. J., et al.
Publicado: (2010)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9dkq0pfirvgr1mejslqoact3ap